Cross-source evidence timeline

Pemvidutide research timeline

Follow 6 selected, directly cited source records from June 24, 2025 through August 31, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

6Selected records
2Source years
1Evidence lanes
August 31, 2026Latest source date

Source year

2026

5 records
Clinical trials · 5
  1. Clinical trials

    ClinicalTrials.gov record NCT07795164

    PeptideScanner retained ClinicalTrials.gov record NCT07795164 at 2026-09-09T19:17:17.076Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was pemvidutide.

  2. Clinical trials

    ClinicalTrials.gov record NCT06987513

    PeptideScanner retained ClinicalTrials.gov record NCT06987513 at 2026-08-10T18:10:03.928Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was pemvidutide.

  3. Clinical trials

    ClinicalTrials.gov record NCT05989711

    PeptideScanner retained ClinicalTrials.gov record NCT05989711 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-18, and PeptideScanner's reviewed identity mapping was pemvidutide.

  4. Clinical trials

    Pemvidutide IMPACT study record updated

    ClinicalTrials.gov lists a completed Pemvidutide study sponsored by Altimmune, Inc.

  5. Clinical trials

    ClinicalTrials.gov record NCT07009860

    PeptideScanner retained ClinicalTrials.gov record NCT07009860 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was pemvidutide.

Source year

2025

1 record
Clinical trials · 1
  1. Clinical trials

    ClinicalTrials.gov record NCT04561245

    PeptideScanner retained ClinicalTrials.gov record NCT04561245 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-24, and PeptideScanner's reviewed identity mapping was pemvidutide.